The FDA clears a 15-year implant for bladder control

The FDA granted 510(k) clearance on 5 August 2026 to Revi Extend, BlueWind Medical’s next-generation implant for urgency urinary incontinence. The device is placed near the ankle in a single outpatient procedure under local anaesthetic and stimulates the posterior tibial nerve, driven by an external wearable worn over the site rather than by electronics inside the body. What this clearance changes, against the Revi system already on the market, is the intended implant life, which goes to fifteen years.

Healio reports the supporting data as a study of 151 women, with 77.8% reaching at least a 50% reduction in incontinence episodes at six months, 82% at nine months, and 79.4% still holding that response at 24 months. BlueWind chief executive Kerry Nelson framed the clearance as continuity rather than a new therapy. A limited United States launch is planned for the fourth quarter of 2026.

Service life is not a clinical endpoint, which is why an approval like this reads as paperwork. It is not: an implant rated for fifteen years instead of a shorter term is the difference between a device a patient lives with and a device a patient replaces.